The Efficacy of the Dual-targeted Drug Combination Regimen Combined with TCb in Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer and Its Impact on Tumor Markers

Abstract

Objective: To investigate the clinical efficacy of the trastuzumab plus pertuzumab (biclusal targeted therapy) combined with the TCb regimen (docetaxel + carboplatin) in neoadjuvant chemotherapy for HER2-positive breast cancer, as well as its impact on serum tumor markers. Methods: A total of 112 HER2-positive breast cancer patients admitted to our hospital between June 2023 and December 2025 were enrolled and randomly assigned into two groups using a random number table: the observation group (n = 56) and the control group (n = 56). The control group received the TCb chemotherapy regimen, while the observation group received the TCb regimen combined with trastuzumab and pertuzumab as dual-targeted therapy; both groups underwent a total of 6 cycles of treatment. The objective response rate (ORR) and pathological complete response (pCR) rate were compared between the two groups. Serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), and carbohydrate antigen 153 (CA153) were measured before and after treatment, and the incidence of adverse reactions was recorded. Results: The observation group exhibited a higher ORR and pCR rate compared to the control group. After treatment, the serum levels of CEA, CA125, and CA153 in the observation group were lower than those in the control group (P <0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: The use of the dual-targeted therapy combined with the TCb regimen can enhance the efficacy of neoadjuvant chemotherapy in HER2-positive breast cancer, reduce serum tumor marker levels, and does not significantly increase the incidence of adverse reactions.